Application of micheliolide dimethylamine

Abstract

The invention provides application of micheliolide dimethylamine (ACT001) to preparation of medicines for treating hepatic fibrosis. The micheliolide dimethylamine (ACT001) is capable of reversing and inhibiting hepatic fibrosis level of organisms, inhibiting hyperplasia of fibrocytes in livers, improving liver blood supply, promoting hepatocyte regeneration and reducing liver inflammatory effects, thereby being remarkably effective in treatment of hepatic fibrosis.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to the application of mimilactone dimethylamine. Background technique [0002] Microlactone dimethylamine is a derivative of balanolide, which is prepared from the natural extract parthenolide, and is referred to as ACT001 in this article. Parthenolide is a sesquiterpene lactone compound purified from the herb tansy, which has anti-inflammatory, anti-tumor, anti-platelet aggregation and other characteristics. It has anti-inflammatory effect by inhibiting the expression of tumor necrosis factor (TNF-α), interleukin-1 (IL-1), IL-12 and cyclooxygenase-2 (COX-2); by inhibiting The activation and phosphorylation of NF-кB promote the apoptosis of cancer cells, and at the same time inhibit the production of L-8 and vascular endothelial growth factor (VEGF), which plays an anti-tumor role; the current research on ACT001 is mainly used for Treatment of diseases such as skin infections, m...

AI Technical Summary

Problems solved by technology

Nucleosides and other drugs used to treat liver fibrosis are only likely to achieve durable responses with long-term treatment and are prone to drug resistance

There are still varying degrees of controversy about the efficacy of some drugs used to treat liver fibrosis clinically.

Images